

2021

“ ” “ ”

“ ” “ ”

2 —

1 —

2021

1

2020 11 6

2020 2929

“ ” “ ” 2020

12

A 9,000

24.36

219,240.00

17,488.45

201,751.55

2020 12

[2020]230Z0290

2

2021

1

21,320.49

2

75,664.99

15,200.00

“

”5,618.77

2021

96,985.48

104,766.07

1,721.83

2021 12 31

106,487.36

0.54

1

2020 12 23

“ ”

2021 12 31

		8110701014002006380	19,769.33
		321130100100426883	27,267.56
		03004343467	4,519.19
		0200098019100013866	5,817.41
		0200098019100013192	30,949.48
		9550880043541600445	8,134.04
		03004354183	10,030.35
	-	-	106,487.36

2021 12 31
96,985.48 1

2021 2 5

213,204,925.63

2021 1

31 [2021]230Z0239

2021 1 28

10.00 10.00

12

2021 12 31 86,120.41

		()	()			
		19,769.33		2021.3.2	2022.3.1	
		27,267.56		2021.3.1		

		30,949.48		2021.3.3	2022.3.2	
		8,134.04		2021.3.12	2023.3.12	

2021 1 28

2021 3~~0~~⁴

2021 12 31

2021

2021

2 —

2021

2021


2021

2 —

1 —

（本页无正文，为《中信证券股份有限公司关于悦康药业集团股份有限公司 2021 年度募集资金存放与实际使用情况的专项核查意见》之签章页）

保荐代表人：



洪立斌



罗 耸



1

2021

				201,751.55						96,985.48		
				-						96,985.48		
				-								
				(1)		(2)	(3)	(2)-(1)	(%)(4)			
		39,000.00	39,000.00	39,000.00	12,340.67	12,340.67	-26,659.33	31.64	—	—	—	
		26,500.00	26,500.00	26,500.00	7,076.41	7,076.41	-19,423.59	26.70	—	—	—	
		10,000.00	10,000.00	10,000.00	—	—	-10,000.00	—	—	—	—	
		8,000.00	8,000.00	8,000.00	—	—	-8,000.00	—	—	—	—	
		5,000.00	5,000.00	5,000.00	495.19	495.19	-4,504.81	9.90	—	—	—	
		17,000.00	17,000.00	17,000.00	11,233.82	11,233.82	-5,766.18	66.08	—	—	—	
		45,000.00	45,000.00	45,000.00	45,020.62	45,020.62	20.62	100.05	—	—	—	

--	--